Pergolide, a synthetic ergoline with potent dopaminergic activity, is used to treat Parkinson disease. The low plasma concentrations of pergolide achieved during therapy complicate the development of a method for its analysis. Because radioimmunoassay successfully measures other structurally related ergolines in physiological fluids, we undertook the development of a radloimmunoassay of pergolide. The detection limit of the radioimmunoassay is 21 ng/L with an optimal working range from 100 to 1000 ng/L. We maximized assay specificity by using a monoclonal antibody that displayed low crossreactivity with pergolide sulfoxide, a major metabolite found in animals. The radioimmunoassay has performed acceptably for >2 years during toxicology studies with rats and rhesus monkeys and in clinical studies involving patients with Parkinson disease. We consider the radioimmunoassay a valid method for quantifying therapeutic concentrations of pergolide in plasma. From the metabolic information and the in vitro structure activity data, we conclude that the RIA is specific for pergolide.
Pergolide is a synthetic ergoline with potent dopaminergic activity (D1 and potent than other ergolines, e.g., bromocriptine (4) (5) (6) (7) , with a mean oral therapeutic dose of 3 mg/day administered in three doses (3, 4). The small therapeutic dosage of pergolide and its extensive metabolism in vivo result in low plasma concentrations of unchanged drug (7, 8) . Consequently, sensitivity has been the major In this study we used pergolide sulfoxide, a major metabolite in animals (8), to screen for monoclonal antibodies that displayed selectivity for pergolide.
Structural characterization of human metabolites has not been possible because of (a) the small dose of pergolide that is tolerated in normal volunteers and (b) the multiplicity of metabolites formed in humans. Tracer studies involving 14C-labeled pergolide indicate that, in humans, pergolide is transformed into highly polar metabolites, with the sulfoxide, sulfone, andN-despropyl metabolites serving as intermediates that undergo secondary metabolism (8); conjugation is not a major route of pergolide metabolism in humans (8) . From the metabolic information and the in vitro structure activity data, we conclude that the RIA is specific for pergolide.
Materials and Methods

Materials
Reagents.
Pergolide 5, 1, 1.5, 2, 3, 4, 8, 12 , 24, and 48 We stored the plasma samples frozen in plastic tubes at -20 #{176}C.
Results
Monoclonal antibody characterization.
Isotype analysis revealed that the monoclonal antibody was an IgG2
immunoglobulin.
Scatchard analysis indicated that the antibody contained a single population of binding sites with an affinity constant of 5.04 x i0 L/mol. To characterize the specificity of the antibody, we evaluated the cross-reactivity of the pergolide derivatives shown in Table 1 in competitive-binding experiments. All of the compounds evaluated were less potent than pergolide for displacing radiolabeled pergolide (Table 2) Figure   2 . The standard curve parameters (mean ± SE; n = 11) for the pergolide RIA were 1.32% ± 0.09% for the nonspecific binding, 40.6% ± 1.67% for the maximum binding, 1.04 ± 0.02 for the slope, and 173 ± 10.5 ng/L for the EDu).
RIA validation.
We estimated the detection limit (sensitivity) of the RIA to be 21 ng/L. We compiled over 2.25 years interassay precision data for plasma control samples from four different studies involving humans, rats, and rhesus monkeys. As shown in Figure 3 samples was 93% at 50, 102% at 100, 100% at 250 and 500, and 87% at 2500 ng/L.
To assess analytical accuracy, we showed that the immunoreactive pergolide in rat plasma after oral administration yielded dilution curves parallel to that for authentic pergolide (Figure 2) . We also demonstrated that the immunoreactive pergolide in rat plasma after a single oral dose of 5 mg/kg was coeluted with standard pergolide during HPLC with a C18 column. We systematically investigated the specificity of the monoclonal antibody by evaluating the cross-reactivity of pergolide metabolites and several synthetic derivatives of pergolide.
Any modification of pergolide at position one, six, or eight reduced cross-reactivity with the monoclonal antibody (Table 2) . Thus, we postulate that the overall stereochemistry of pergolide is important for defining the antibody-binding epitope. Of the previously characterized metabolites of pergolide tested, all but the sulfone were <5% as potent as pergolide at displacing radiolabeled pergolide. In humans, pergolide is transformed into highly polar metabolites, with the sulfoxide, sulfone, and N-despropyl metabolites probably serving as intermediates that undergo secondary metabolism (8). Thus, based on the specificity of the monoclonal antibody (Table 2 ) and the nature and multiplicity of human metabolites, we conclude that it is unlikely that any of the pergolide metabolites can accumulate in the circulation in sufficient concentration to interfere in the RIA.
We selected an antibody dilution of 50000-fold for use in the RIA. Even though we can detect displacement of tritiated pergolide at concentrations s10 ngfL, we established 21 ng/L as the routine quantification limit of the RIA. We determined empirically that a 50 g/L suspension of charcoal was optimal for use in the RIA. At lower percentages of charcoal the nonspecific binding increased, presumably because of increased binding of tritiated pergolide to low-affinity sites on plasma proteins.
We assessed RIA precision by compiling data for plasma control samples over 2.25 years. The interassay CV of the RIA was <15% for concentrations of pergolide between 100 and 1000 ngfL, increasing to 30% for pergolide concentrations <100 ngfL or >1000 ng/L (Figure 3) . For all studies the recovery estimates for the plasma controls ranged from 87% to 102%. Thus, we conclude the optimal working range of the RIA extends from 100 to 1000 ngfL.
Test samples having a high concentration
of pergolide are reanalyzed after dilution with drug-free plasma. We validated the accuracy of the RIA by demonstrating that the dilution curves for immunoreactive pergolide in rat plasma parallel those for authentic pergolide (Figure 2) In summary, we report the development of a sensitive RIA method for determining pergolide in plasma. Assay specificity was maximized by using a monoclonal antibody that displayed low cross-reactivity with pergolide metabolites.
We used the RIA to measure pergolide in plasma from rats, rhesus monkeys, and humans.
We
conclude that the RIA is sufficient for routine measure- 
